Novartis C.E.O. Defends Company’s Decision to Withhold False Data From the F.D.A.
The chief executive of Novartis on Wednesday defended the company’s decision to delay telling the Food and Drug Administration about manipulated data involving its $2.1 million gene therapy treatment, saying that it “thoroughly, aggressively” investigated the issue and that patient safety was never threatened. Vas Narasimhan, the chief executive, also indicated in a call with…